Alder BioPharmaceuticals® to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 31, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2018 16:45 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Carlos Campoy Chief Financial Officer
December 11, 2018 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences
November 08, 2018 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results
November 05, 2018 16:08 ET
|
Alder BioPharmaceuticals, Inc.
- Biologics License Application (BLA) submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include positive results from pharmacokinetic comparability study - -...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results
October 29, 2018 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab
October 23, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2018 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2018 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2018 17:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...